Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Total Non-Current Liabilities (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $638.6 million as the latest value for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities rose 2.82% year-over-year to $638.6 million; the TTM value through Mar 2026 reached $638.6 million, up 2.82%, while the annual FY2025 figure was $693.3 million, 11.75% up from the prior year.
  • Total Non-Current Liabilities hit $638.6 million in Q1 2026 for Phathom Pharmaceuticals, down from $693.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $693.3 million in Q4 2025 and bottomed at $103.5 million in Q1 2022.
  • Average Total Non-Current Liabilities over 5 years is $437.1 million, with a median of $495.3 million recorded in 2024.
  • Year-over-year, Total Non-Current Liabilities skyrocketed 127.86% in 2024 and then grew 2.82% in 2026.
  • Phathom Pharmaceuticals' Total Non-Current Liabilities stood at $232.1 million in 2022, then surged by 105.45% to $476.9 million in 2023, then soared by 30.09% to $620.4 million in 2024, then grew by 11.75% to $693.3 million in 2025, then dropped by 7.9% to $638.6 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $638.6 million, $693.3 million, and $651.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.